Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

NAOV vs DBVT vs ALKS vs ARAY

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NAOV
NanoVibronix, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$513K
5Y Perf.-100.0%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-55.4%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+107.2%
ARAY
Accuray Incorporated

Medical - Devices

HealthcareNASDAQ • US
Market Cap$35M
5Y Perf.-61.4%

NAOV vs DBVT vs ALKS vs ARAY — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NAOV logoNAOV
DBVT logoDBVT
ALKS logoALKS
ARAY logoARAY
IndustryMedical - DevicesBiotechnologyBiotechnologyMedical - Devices
Market Cap$513K$1712.35T$5.90B$35M
Revenue (TTM)$3M$0.00$1.56B$429M
Net Income (TTM)$-4M$-168M$153M$-46M
Gross Margin30.0%65.4%26.8%
Operating Margin-351.8%12.3%-5.1%
Forward P/E24.8x
Total Debt$116K$22M$70M$176M
Cash & Equiv.$752K$194M$1.12B$57M

NAOV vs DBVT vs ALKS vs ARAYLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NAOV
DBVT
ALKS
ARAY
StockMay 20Mar 26Return
NanoVibronix, Inc. (NAOV)1000.0-100.0%
DBV Technologies S.… (DBVT)10044.6-55.4%
Alkermes plc (ALKS)100207.2+107.2%
Accuray Incorporated (ARAY)10038.6-61.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: NAOV vs DBVT vs ALKS vs ARAY

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. NanoVibronix, Inc. is the stronger pick specifically for growth and revenue expansion. DBVT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
NAOV
NanoVibronix, Inc.
The Growth Play

NAOV is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 12.0%, EPS growth 35.2%, 3Y rev CAGR 14.7%
  • 12.0% revenue growth vs DBVT's -100.0%
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
  • +110.4% vs NAOV's -95.7%
Best for: income & stability
ALKS
Alkermes plc
The Long-Run Compounder

ALKS carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • -11.0% 10Y total return vs DBVT's -87.0%
  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.06, current ratio 3.55x
  • 9.8% margin vs NAOV's -133.0%
Best for: long-term compounding and sleep-well-at-night
ARAY
Accuray Incorporated
The Secondary Option

ARAY lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthNAOV logoNAOV12.0% revenue growth vs DBVT's -100.0%
Quality / MarginsALKS logoALKS9.8% margin vs NAOV's -133.0%
Stability / SafetyALKS logoALKSBeta 1.06 vs ARAY's 2.42, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs NAOV's -95.7%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

NAOV vs DBVT vs ALKS vs ARAY — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NAOVNanoVibronix, Inc.

Segment breakdown not available.

DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
ARAYAccuray Incorporated
FY 2025
Product
51.8%$238M
Service
48.2%$221M

NAOV vs DBVT vs ALKS vs ARAY — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 4 of 6 comparable metrics.

ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to NAOV's -133.0%. On growth, NAOV holds the edge at +92.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNAOV logoNAOVNanoVibronix, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcARAY logoARAYAccuray Incorpora…
RevenueTrailing 12 months$3M$0$1.6B$429M
EBITDAEarnings before interest/tax-$9M-$112M$212M-$15M
Net IncomeAfter-tax profit-$4M-$168M$153M-$46M
Free Cash FlowCash after capex-$7M-$151M$392M-$28M
Gross MarginGross profit ÷ Revenue+30.0%+65.4%+26.8%
Operating MarginEBIT ÷ Revenue-3.5%+12.3%-5.1%
Net MarginNet income ÷ Revenue-133.0%+9.8%-10.8%
FCF MarginFCF ÷ Revenue-2.7%+25.1%-6.5%
Rev. Growth (YoY)Latest quarter vs prior year+92.0%+28.2%-7.4%
EPS Growth (YoY)Latest quarter vs prior year+129.2%+91.5%-4.1%-6.1%
ALKS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ARAY leads this category, winning 4 of 4 comparable metrics.

On an enterprise value basis, ARAY's 11.0x EV/EBITDA is more attractive than ALKS's 17.3x.

MetricNAOV logoNAOVNanoVibronix, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcARAY logoARAYAccuray Incorpora…
Market CapShares × price$512,711$1712.35T$5.9B$35M
Enterprise ValueMkt cap + debt − cash-$123,289$1712.35T$4.9B$154M
Trailing P/EPrice ÷ TTM EPS-0.14x-0.76x24.76x-18.91x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.25x10.99x
Price / SalesMarket cap ÷ Revenue0.20x4.00x0.08x
Price / BookPrice ÷ Book value/share0.82x0.66x3.28x0.37x
Price / FCFMarket cap ÷ FCF12.28x
ARAY leads this category, winning 4 of 4 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 8 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARAY's 2.17x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs NAOV's 2/9, reflecting strong financial health.

MetricNAOV logoNAOVNanoVibronix, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcARAY logoARAYAccuray Incorpora…
ROE (TTM)Return on equity-8.4%-130.2%+8.8%-77.5%
ROA (TTM)Return on assets-6.6%-89.0%+5.4%-10.1%
ROICReturn on invested capital-7.7%+18.9%+3.0%
ROCEReturn on capital employed-139.7%-145.7%+14.2%+2.8%
Piotroski ScoreFundamental quality 0–92476
Debt / EquityFinancial leverage0.19x0.13x0.04x2.17x
Net DebtTotal debt minus cash-$636,000-$172M-$1.0B$119M
Cash & Equiv.Liquid assets$752,000$194M$1.1B$57M
Total DebtShort + long-term debt$116,000$22M$70M$176M
Interest CoverageEBIT ÷ Interest expense-23.76x-189.82x32.30x-1.86x
ALKS leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $9 for NAOV. Over the past 12 months, DBVT leads with a +110.4% total return vs NAOV's -95.7%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs NAOV's -83.3% — a key indicator of consistent wealth creation.

MetricNAOV logoNAOVNanoVibronix, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcARAY logoARAYAccuray Incorpora…
YTD ReturnYear-to-date-22.4%+4.9%+25.3%-65.5%
1-Year ReturnPast 12 months-95.7%+110.4%+16.5%-78.4%
3-Year ReturnCumulative with dividends-99.5%+19.7%+14.5%-91.8%
5-Year ReturnCumulative with dividends-99.9%-69.1%+60.9%-93.9%
10-Year ReturnCumulative with dividends-100.0%-87.0%-11.0%-94.5%
CAGR (3Y)Annualised 3-year return-83.3%+6.2%+4.6%-56.6%
Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than ARAY's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs NAOV's 4.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNAOV logoNAOVNanoVibronix, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcARAY logoARAYAccuray Incorpora…
Beta (5Y)Sensitivity to S&P 5001.49x1.26x1.06x2.42x
52-Week HighHighest price in past year$44.50$26.18$36.60$2.10
52-Week LowLowest price in past year$0.99$7.53$25.17$0.28
% of 52W HighCurrent price vs 52-week peak+4.3%+76.3%+96.7%+14.0%
RSI (14)Momentum oscillator 0–10045.148.160.258.4
Avg Volume (50D)Average daily shares traded335K252K2.3M1.4M
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 24.3% for ALKS (target: $44).

MetricNAOV logoNAOVNanoVibronix, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcARAY logoARAYAccuray Incorpora…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$46.33$44.00
# AnalystsCovering analysts1528
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ARAY leads in 1 (Valuation Metrics). 1 tied.

Best OverallAlkermes plc (ALKS)Leads 3 of 6 categories
Loading custom metrics...

NAOV vs DBVT vs ALKS vs ARAY: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is NAOV or DBVT or ALKS or ARAY a better buy right now?

For growth investors, NanoVibronix, Inc.

(NAOV) is the stronger pick with 12. 0% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — NAOV or DBVT or ALKS or ARAY?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -99. 9% for NanoVibronix, Inc. (NAOV). Over 10 years, the gap is even starker: ALKS returned -11. 0% versus NAOV's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — NAOV or DBVT or ALKS or ARAY?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately 128% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.

04

Which is growing faster — NAOV or DBVT or ALKS or ARAY?

By revenue growth (latest reported year), NanoVibronix, Inc.

(NAOV) is pulling ahead at 12. 0% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Accuray Incorporated grew EPS 90. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, NAOV leads at 14. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — NAOV or DBVT or ALKS or ARAY?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -144. 8% for NanoVibronix, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -140. 0% for NAOV. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — NAOV or DBVT or ALKS or ARAY?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is NAOV or DBVT or ALKS or ARAY better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

06)). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -11. 0%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between NAOV and DBVT and ALKS and ARAY?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

NAOV

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 46%
  • Gross Margin > 18%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

ARAY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.